文献速递糖尿病

Bigfoot Unity 真实世界前瞻性研究观察到的血糖与心理社会获益:6个月分析

Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

BURST研究(NCT05088265)纳入102例使用多次每日胰岛素注射的1型或2型糖尿病患者,前瞻性评估Bigfoot Unity糖尿病管理系统6个月的真实世界血糖控制。平均HbA1c从基线9.1±1.7%降至6个月8.0±1.2%(平均差-1.1%,95%CI -1.4至-0.8,P<.001)。6个月时葡萄糖目标范围内时间(70-180 mg/dL)为56±23%,低于70 mg/dL时间为1.0±1.4%,低于54 mg/dL时间为0.04±0.14%。

要点

  • 使用Bigfoot Unity系统6个月后平均HbA1c较基线下降1.1%(95%CI -1.4至-0.8,P<.001)。
  • 6个月时低于70 mg/dL时间1.0±1.4%、低于54 mg/dL时间0.04±0.14%,低于既定目标。
  • 4例参与者发生6次严重低血糖事件(无系统相关),无糖尿病酮症酸中毒事件。

核心结论

  • 在主要为老年2型糖尿病使用多次每日胰岛素注射的患者中,使用Bigfoot Unity系统6个月出现持续的血糖改善,低血糖频率显著低于低于70 mg/dL和低于54 mg/dL时间分别<4%和<1%的既定目标。

研究设计与样本

  • BURST研究(NCT05088265)的6个月前瞻性分析,纳入1型或2型糖尿病患者,使用Bigfoot Unity系统进行多次每日胰岛素注射。
  • 符合方案队列共102例参与者,中位年龄59岁,87%为2型糖尿病,42%既往使用连续葡萄糖监测,62%为非西班牙裔白人,59%为女性。

主要发现

  • 平均HbA1c从基线9.1±1.7%降至6个月8.0±1.2%(平均差-1.1%,95%CI -1.4至-0.8,P<.001)。
  • 6个月时葡萄糖目标范围内时间(70-180 mg/dL)为56±23%,低于70 mg/dL时间为1.0±1.4%,低于54 mg/dL时间为0.04±0.14%。
  • 符合方案队列中4例参与者发生6次严重低血糖事件(无系统相关),无糖尿病酮症酸中毒事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The Bigfoot Unity Diabetes Management System integrates Abbott FreeStyle Libre 2 continuous glucose monitoring (CGM) data into a smart insulin pen cap and mobile app, enabling clinician-directed insulin dose recommendations and real-time alerts. OBJECTIVE: The objective was to analyze real-world 6-month glycemic control in a prospective study for individuals using the System for multiple daily insulin injections (MDI). METHODS: We conducted a 6-month analysis from the BURST study (NCT05088265) of individuals with type 1 or type 2 diabetes (T2D). Participants reported baseline demographics, adverse events, and other survey data electronically. Either at-home kit or electronic medical record glycated hemoglobin A1c (HbA1c) data were collected. RESULTS: Of 102 participants in the per protocol cohort, median age was 59 years, 87% had T2D, 42% used CGM previously, 62% were White non-Hispanic, and 59% female. Mean HbA1c decreased from 9.1 ± 1.7% at baseline to 8.0 ± 1.2% at 6 months (mean difference -1.1%, 95% CI -1.4 to -0.8, P < .001). At 6 months, time in range (70-180 mg/dL), time at < 70 mg/dL, and time at < 54 mg/dL were 56 ± 23%, 1.0 ± 1.4%, and 0.04 ± 0.14%, respectively. Six severe hypoglycemia events occurred in 4 participants (none System-related) and no diabetic ketoacidosis events occurred in the per protocol cohort. CONCLUSION: In this study primarily of older adults with T2D using MDI, durable glycemic improvement occurred using the System at 6 months, with the frequency of hypoglycemia being substantially below established targets of < 4% and < 1% for time below 70 and 54 mg/dL, respectively.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tillman JB, Beck RW, Polonsky WH, et al. Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis. J Clin Endocrinol Metab. 2025. PMID: 39546625. doi:10.1210/clinem/dgae778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。